Nurix Q3 report, program updates

Nurix Therapeutics (Nasdaq: NRIX) reported Q3 2025 results and program updates on Oct 9, 2025. The company plans to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL in H2/Q4 2025, including a single‑arm path for potential accelerated approval and a randomized Phase 3 confirmatory trial. Encore Phase 1 data showed ORR 80.9% in CLL and ORR 84.2% in WM. Preclinical data for IRAK4 degrader GS-6791 were presented. Cash and marketable securities were $428.8M as of Aug 31, 2025.

https://www.stocktitan.net/news/NRIX/nurix-therapeutics-reports-third-quarter-2025-financial-results-and-n2i7a8g921gq.html